Analysis of the key themes driving M&A activity reveals that precision and personalized medicine accounted for 12 pharmaceutical deals announced in Q4 2023, worth a total value of $3bn. The $1.2bn acquisition of Gracell Biotechnologies by AstraZeneca was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.

Smarter leaders trust GlobalData

In value terms, precision and personalized medicine-related deal activity increased by 88% in Q4 2023 compared with the previous quarter’s total of $1.6bn and rose by 79% as compared to Q4 2022. Related deal volume decreased by 20% in Q4 2023 versus the previous quarter and was 9% higher than in Q4 2022.

The top-ranked financial advisors supporting these M&A deals in Q4 2023 were SVB Financial Group; Centerview Partners; Toronto-Dominion Bank with 8, 6, 4 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q4 2023 were Goodwin Procter; Gibson, Dunn & Crutcher; Fried, Frank, Harris, Shriver & Jacobson with 6, 5, 4 deals respectively.

For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.

This content was updated on 8 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Acquisition, Asset transactions and Mergers.